Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond

SFT is an ultrarare mesenchymal ubiquitous tumor, with an incidence rate <1 case/million people/year. The fifth WHO classification published in April 2020 subdivided SFT into three categories: benign (locally aggressive), NOS (rarely metastasizing), and malignant. Recurrence can occur in up to 10...

Full description

Bibliographic Details
Main Authors: Axel de Bernardi, Armelle Dufresne, Florence Mishellany, Jean-Yves Blay, Isabelle Ray-Coquard, Mehdi Brahmi
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
SFT
rare sarcoma
antiangiogenics
immune-checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/4/1064

Internet

https://www.mdpi.com/2072-6694/14/4/1064

Similar Items